Global Oral Proteins and Peptides Market Size, Share, Revenue Analysis & Trends Report Segmented by Molecule (Semaglutide, Calcitonin), Drug Class (GLP-1 & CGRP Receptor Agonists), Formulation (Tablets, Capsules, Oral Solutions), Therapeutic Area, End-user & Regional Forecast to 2031
The global oral proteins and peptides market size is expected to grow at a CAGR of 16% during the forecast period. The growth is driven by the rising burden of chronic and lifestyle-related diseases, advancements in drug-delivery technologies, growing patient preference for the oral route of administration, and increasing R&D investments by pharma and biotech companies. However, the high cost of drug development and limited bioavailability and GI-related constraints remain key restraints to market expansion. To learn more about the research report, download a sample report.
Oral administration of protein and peptide drugs offers an appealing alternative to injections, especially for treating chronic conditions like diabetes and hormone-related disorders. To improve absorption and stability, researchers have developed advanced drug delivery systems. Nanocarriers like liposomes and polymeric nanoparticles can encase the drug, shielding it from enzymatic breakdown and promoting uptake. Enteric coatings allow drugs to bypass the stomach and release in more favourable conditions of the intestine. Mucoadhesive formulations extend retention time at the absorption site, increasing the chance of systemic entry. Other approaches include using permeability enhancers that temporarily open tight junctions between intestinal cells and modifying the chemical structure of the drug to improve resistance to degradation.
To learn more about this report, download the PDF brochure
The rising burden of chronic disease is accelerating the expansion of the oral proteins and peptides market
The growing burden of chronic diseases is reshaping the landscape of the oral proteins and peptides market, acting as a catalyst for innovation. Conditions such as type 2 diabetes, obesity, inflammatory bowel disease, and autoimmune disorders are not only increasing but also demanding more patient-friendly treatment options. Traditional injectable therapies, while effective, often pose challenges like pain, inconvenience, and reduced adherence, especially for patients requiring long-term management. This has led to a shift towards oral delivery systems, which are a more comfortable and convenient alternative.
Pharmaceutical companies are investing in advanced technologies that protect proteins and peptides from enzymatic degradation in the gastrointestinal tract. Techniques such as enteric coatings, nanoparticle carriers, and permeation enhancers are being refined to improve bioavailability and therapeutic performance. Oral semaglutide, for instance, has emerged as a breakthrough in treating type 2 diabetes and obesity, demonstrating that oral biologics can match the efficacy of injectables while enhancing patient experience.
Additionally, the rise in chronic diseases has fuelled the expansion of oral peptides beyond metabolic disorders, in other therapeutic areas, including neurological conditions like Alzheimer’s, hormonal imbalances, and rare genetic disorders. To conclude, with the increasing geriatric populations and lifestyle-related health issues globally, the demand for non-invasive, effective treatments is expected to accelerate.
To learn more about this report, download the PDF brochure
AI integration in drug discovery is fuelling the market growth
Artificial Intelligence (AI) is becoming an integral part of the development of oral proteins and peptides, aiming to overcome their limited bioavailability and GI-related constraints. Tools like AlphaFold and BioEmu have enabled the prediction of how proteins react with physiological barriers in the human body, which is important for improving their stability and absorption in the digestive system. Deep generative models such as generative adversarial networks (GANs), variational autoencoder (VAE) and diffusion models are being used to create new therapeutic peptides with desired properties such as high stability and target specificity.
AI systems are also being used to forecast oral absorption, toxicity, and formulation techniques, reducing the need for time-consuming and expensive trial-and-error laboratory screening methods. For example, AI Platforms like Latent-X allow scientists to design protein binders and macrocycles without needing to write code, making the design process more accessible. AI platforms have enabled researchers to work more efficiently and expand the use of peptides to treat conditions like diabetes, obesity, and Alzheimer’s. These AI-driven tools and insights are helping push the boundaries of what oral drug delivery can achieve in future.
Competitive Landscape Analysis
The global oral proteins and peptides market is marked by the presence of established and emerging market players such as Novo Nordisk A/S; Abbvie Inc.; Oramed Pharmaceuticals Inc.; Pfizer Inc.; Rani Therapeutics Inc.; Acadia Pharmaceuticals Inc.; Johnson and Johnson; AstraZeneca PLC; Aurinia Pharmaceuticals Inc., and Amgen Inc., among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2025 |
| Historical Data | 2024 – 2025 |
| Forecast Period | 2026 – 2031 |
| Growth Rate | 16% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Molecule, Drug Class, Formulation, Therapeutic Area, and End-user |
| Regional Scope |
|
| Key Companies Mapped | Novo Nordisk A/S; Abbvie Inc.; Oramed Pharmaceuticals Inc.; Pfizer Inc.; Rani Therapeutics Inc.; Acadia Pharmaceuticals Inc.; Johnson and Johnson; AstraZeneca PLC; Aurinia Pharmaceuticals Inc.; and Amgen Inc.; among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Oral Proteins and Peptides Market Segmentation
This report by Medi-Tech Insights provides the size of the global oral proteins and peptides market at the regional- and country-level from 2024 to 2031. The report further segments the market based on molecule, drug class, formulation, therapeutic area, and end-user.
Market Size & Forecast (2024-2031), By Molecule, USD Million
- Semaglutide
- Calcitonin
- Linaclotide
- Trofinetide
- Voclosporin
- Plecanatide
- Others
Market Size & Forecast (2024-2031), By Drug Class, USD Million
- GLP-1 Receptor Agonists
- CGRP Receptor Agonists
- GC-C Agonists
- GPE
- Others
Market Size & Forecast (2024-2031), By Formulation, USD Million
- Tablets
- Capsules
- Oral Solutions
Market Size & Forecast (2024-2031), By Therapeutic Area, USD Million
- Diabetes
- CNS Disorders
- Gastroenterology
- Genetic Disorders
- Nephrology
- Others
Market Size & Forecast (2024-2031), By End-user, USD Million
- Hospitals & Specialty Clinics
- Home Care Settings
- Long-term Care Facilities
- Others
Market Size & Forecast (2024-2031), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the oral proteins and peptides market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the oral proteins and peptides market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2026-2027)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Oral Proteins and Peptides Market Snapshot (2026-2031)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Growing burden of chronic and lifestyle-related diseases
- Advancements in oral drug delivery technologies
- Growing patient preference for oral route of administration
- Increased R&D investments by pharma and biotech companies
- Adoption of AI-driven predictive modelling in formulation development
- Restraints
- High cost of drug development
- Limited bioavailability and GI-related constraints
- Manufacturing complexity and scalability limitations
- Opportunities
- Expansion into new therapeutic areas
- Growing focus on personalized medicine
- Increasing strategic collaboration among biopharma and tech companies accelerates innovation
- Key Market Trends
- Integration of AI in drug delivery
- Rising focus on plant-based and naturally derived peptide sources
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Molecule, USD Million
- Introduction
- Semaglutide
- Calcitonin
- Linaclotide
- Trofinetide
- Voclosporin
- Plecanatide
- Others
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Drug Class, USD Million
- Introduction
- GLP-1 Receptor Agonists
- CGRP Receptor Agonists
- GC-C Agonists
- GPE
- Others
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Formulation, USD Million
- Introduction
- Tablets
- Capsules
- Oral Solutions
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Therapeutic Area, USD Million
- Introduction
- Diabetes
- CNS Disorders
- Gastroenterology
- Genetic Disorders
- Nephrology
- Others
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By End-user, USD Million
- Introduction
- Hospitals & Specialty Clinics
- Home Care Settings
- Long-term Care Settings
- Others
- Global Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Region, USD Million
- Introduction
- North America Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Country, USD Million
- US
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Canada
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- US
- Europe Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Country, USD Million
- UK
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Germany
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- France
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Italy
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Spain
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Europe
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- UK
- Asia Pacific (APAC) Oral Proteins and Peptides Market Size & Forecast (2024-2031), By Country, USD Million
- China
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Japan
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- India
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- China
- Latin America (LATAM) Oral Proteins and Peptides Market Size & Forecast (2024-2031), USD Million
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Middle East & Africa (MEA) Oral Proteins and Peptides Market Size & Forecast (2024-2031), USD Million
- Market Size & Forecast, By Molecule (USD Million)
- Market Size & Forecast, By Drug Class (USD Million)
- Market Size & Forecast, By Formulation (USD Million)
- Market Size & Forecast, By Therapeutic Area (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2025)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2023-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Novo Nordisk A/S
- AbbVie Inc.
- Oramed Pharmaceuticals Inc.
- Pfizer Inc.
- Rani Therapeutics Inc.
- Acadia Pharmaceuticals Inc.
- Johnson and Johnson
- AstraZeneca PLC
- Aurinia Pharmaceuticals Inc.
- Amgen Inc.
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals & Specialty Clinics, and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
Features of the Report
- Comprehensive Market Coverage
- Market Size and Forecast
- Geographic & Segment Deep Dives
- Strategic Insights & Competitive Landscape
- Timely & Updated Data
- Growth Indicators & Future Outlook
- Quick Turnaround on Queries
- Analyst Support
- Report Customization Available
- Reports in PDF & Excel
